Zydus Lifesciences Limited (BOM:532321)

Market Cap	1.08T +22.7%
Revenue (ttm)	271.48B +16.8%
Net Income	50.40B +11.4%
EPS	50.09 +11.4%
Shares Out	n/a
PE Ratio	21.52
Forward PE	26.06
Dividend	1.00 (0.09%)
Ex-Dividend Date	Jul 24, 2026

Volume	186,395
Open	1,099.85
Previous Close	1,085.95
Day's Range	1,071.30 - 1,115.00
52-Week Range	835.85 - 1,115.00
Beta	n/a
Analysts	Hold
Price Target	1,066.50 (-1.04%)
Earnings Date	May 19, 2026

About Zydus Lifesciences

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pi...

• Industry: Pharmaceutical Preparations
• Founded: 1952
• Employees: 27,917
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 532321

Financial Performance

In fiscal year 2026, Zydus Lifesciences's revenue was 271.48 billion, an increase of 16.81% compared to the previous year's 232.42 billion. Earnings were 50.40 billion, an increase of 11.37%.